High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy
- 18 March 2013
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 85 (5), 893-898
- https://doi.org/10.1002/jmv.23539
Abstract
Cytomegalovirus infection (CMV) in solid organ transplant recipients is a major clinical problem. The aim of this study was to evaluate the incidence of CMV infection and its association with mortality during the first year after transplantation in a large solid organ transplant cohort at the Royal Infirmary of Edinburgh between January 2006 and April 2009. Data including the use of CMV prophylaxis, nature of CMV disease, treatment and deceased date (when appropriate) was collected retrospectively using hospital databases and patient notes for all transplanted patients with detectable CMV viraemia. The outcomes between recipients of kidney and liver transplants in the four CMV donor/recipient serostatus categories (D+R+, D−R−, D+R−, D−R+) were compared. A total of 428 individuals were included. Despite the administration of valganciclovir prophylaxis, CMV disease (syndrome or end-organ involvement) was diagnosed within the year of transplantation in the D+R−-group in 31.3% of liver and 19.2% of kidney recipients. All D+R− transplant recipients that received CMV-prophylaxis presented with late-onset CMV disease. Furthermore, the rate of CMV disease in the D+R+-group was markedly higher in renal graft recipients compared to liver recipients (22% vs. 5%). The highest mortality was observed among the D+R+ liver and kidney graft recipients with CMV infection. The high incidence of late-onset CMV disease in D+R− transplant recipients receiving CMV prophylaxis demonstrates that CMV disease remains an important problem after organ transplantation. Furthermore, the surprisingly high mortality in the D+R+-transplant patients with CMV viraemia highlights the need for proactive monitoring of this group. J. Med. Virol. 85:893–898, 2013.This publication has 30 references indexed in Scilit:
- Importance of the cytomegalovirus seropositive recipient as a contributor to disease burden after solid organ transplantationJournal of Clinical Virology, 2012
- Summary of the British Transplantation Society Guidelines for the Prevention and Management of CMV Disease After Solid Organ TransplantationTransplantation, 2011
- The ‘Indirect’ Effects of Cytomegalovirus InfectionAmerican Journal of Transplantation, 2009
- CMV Mismatch Does Not Affect Patient and Graft Survival in UK Renal Transplant RecipientsTransplantation, 2009
- Valganciclovir for Cytomegalovirus Prevention in Solid Organ Transplant Patients: An Evidence-Based Reassessment of Safety and EfficacyPLOS ONE, 2009
- Delayed-Onset Primary Cytomegalovirus Disease and the Risk of Allograft Failure and Mortality after Kidney TransplantationClinical Infectious Diseases, 2008
- Donor and recipient CMV serostatus and antigenemia after renal transplantation: An analysis of 486 patientsJournal of Clinical Virology, 2008
- An assessment of interactions between hepatitis C virus and herpesvirus reactivation in liver transplant recipients using molecular surveillanceLiver Transplantation, 2007
- EditorialTransplant Infectious Disease, 2001
- SYMPTOMATIC CYTOMEGALOVIRUS INFECTION IN SEROPOSITIVE KIDNEY RECIPIENTS: REINFECTION WITH DONOR VIRUS RATHER THAN REACTIVATION OF RECIPIENT VIRUSThe Lancet, 1988